Repros Soars -- and AbbVie Might Suffer

If you watch television, you've probably come across a commercial for AndroGel, AbbVie's (NYSE: ABBV  ) blockbuster prescription gel for treating low testosterone levels. The technical term for the ailment is hypogonadism, and it's a $2 billion market -- and growing. Markets like that don't come without admirers, and in this case one of those is Repros Therapeutics (NASDAQ: RPRX  ) . The company is developing an oral drug for secondary hypogonadism called Androxal, and in the following video Brenton Flynn discusses why its stock soared today.

Is Repros the least of AbbVie's worries?
In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking, and as an added bonus, you'll receive a full year of free analyst updates as significant news hits. Simply click here now to claim your copy today.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2270030, ~/Articles/ArticleHandler.aspx, 4/17/2014 12:18:59 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement